🇺🇸 FDA
Patent

US 7619005

Methods for treating cognitive impairment in humans with Multiple Sclerosis

granted A61KA61K31/137A61K31/4458

Quick answer

US patent 7619005 (Methods for treating cognitive impairment in humans with Multiple Sclerosis) held by Cognition Pharmaceuticals, LLC expires Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cognition Pharmaceuticals, LLC
Grant date
Tue Nov 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/137, A61K31/4458